Julie R. Nangia
Expertise in
8
conditions

Dr. Julie R. Nangia

Hematology Oncology | Oncology | Obstetrics and Gynecology
1502 Taub Loop, 
Houston, TX 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
8
conditions
1502 Taub Loop, 
Houston, TX 

Overview

Dr. Julie Nangia is a medical oncologist who specializes in the care of patients with breast cancer. Dr. Nangia is Medical Director of Breast Oncology at the Breast Care Center at the Dan L Duncan Comprehensive Cancer Center and an Associate Professor of Medicine at the Lester and Sue Smith Breast Center at Baylor College of Medicine. She is also the Director of the Breast Cancer Prevention and High Risk Clinic at BCM, where she is a Faculty Senator.Dr. Nangia’s clinical interests include: hereditary breast cancer, breast cancer prevention, and metastatic triple negative breast cancer.Dr. Nangia received her medical degree from the University of Missouri-Kansas City. She completed her residency in internal medicine at The University of Texas Health Science Center in Houston and a hematology-oncology fellowship at Rush University Medical Center in Chicago, Illinois.Dr. Nangia is board certified in internal medicine and medical oncology.

Dr. Nangia is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Familial Pancreatic Cancer, and HER-2 Positive Breast Cancer.

She is actively involved in clinical research, co-authoring 32 peer reviewed articles and participating in 13 clinical trials. Dr. Nangia is currently accepting new patients.

Specialties

Hematology Oncology
Oncology
Obstetrics and Gynecology

Licenses

Internal Medicine in TX

Fellowships

Internal Medicine Fellowship at Rush University Medical Center 01/ - Chicago - 2010

Hospital Affiliations

Baylor St Lukes Medical Center
Harris Health
Baylor St. Luke's Medical Center - Houston, TX

Languages Spoken

English
Spanish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

BAYLOR COLLEGE OF MEDICINE
1502 Taub Loop, Houston, TX 77030
Other Locations
BAYLOR COLLEGE OF MEDICINE
2525 A Holly Hall St, Unit 3c, Houston, TX 77054
BAYLOR COLLEGE OF MEDICINE
6770 Bertner Ave, Suite C 350, Houston, TX 77030
BAYLOR COLLEGE OF MEDICINE
7200 Cambridge St, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Atezolizumab, Olaparib
Study Phase: Phase 2
A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer
A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 2
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions
TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions
Enrollment Status: Completed
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Cancer: A Co-Clinical Trial With Genoproteomic Discovery
CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Cancer: A Co-Clinical Trial With Genoproteomic Discovery
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2025
Intervention Type: Drug
Study Drugs: Docetaxel, Carboplatin
Study Phase: Phase 2
A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination With Palbociclib in Subjects With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination With Palbociclib in Subjects With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: August 09, 2024
Intervention Type: Drug
Study Drugs: ZN-c5, Palbociclib
Study Phase: Phase 1/Phase 2
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Procedure, Drug
Study Phase: Phase 2
A Randomized, Controlled Trial of High Dose vs. Standard Dose Vitamin D for Aromatase-Inhibitor Induced Arthralgia in Breast Cancer Survivors
A Randomized, Controlled Trial of High Dose vs. Standard Dose Vitamin D for Aromatase-Inhibitor Induced Arthralgia in Breast Cancer Survivors
Enrollment Status: Terminated
Publish Date: August 09, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

32 Total Publications

VEMORA: Vaginal Estrogen versus non-hormonal MOisturizer in women Receiving Aromatase inhibitors: a randomized, controlled trial.
VEMORA: Vaginal Estrogen versus non-hormonal MOisturizer in women Receiving Aromatase inhibitors: a randomized, controlled trial.
Journal: Breast cancer research and treatment
Published: March 10, 2026
Similar Doctors
Expertise in
7
conditions
Dr. Mothaffar F. Rimawi
Hematology Oncology | Oncology
Expertise in
7
conditions
Dr. Mothaffar F. Rimawi
Hematology Oncology | Oncology
Referral may be required
Before you request

Baylor College Of Medicine

7200 Cambridge St, 
Houston, TX 
 (0.8 miles away)
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Dr. Mothaffar F. Rimawi is a board-certified medical oncologist specializing in breast cancer care and research. He is Professor at the Department of Medicine, Section of Hematology and Oncology at Baylor College of Medicine. Dr. Rimawi is also Executive Medical Director & Associate Director of Clinical Affairs and Co-Leader of the Breast Cancer Program at BCM’s Dan L Duncan Comprehensive Cancer Center. Additionally, he serves as Chief of the Oncology Service Line at St Luke's Health in Houston.Dr. Rimawi’s professional interests include: the diagnosis, treatment and management of breast cancer; clinical trials in breast cancer; neoadjuvant therapy; targeted therapy and biomarkers in breast cancer; treatment resistance to ER and HER2-targeted therapies in breast cancer; locally advanced breast cancer; and breast disease and cancer.Dr. Rimawi received his medical degree from the University of Jordan in Amman, Jordan. He completed his residency in Internal Medicine and fellowships in Medical Oncology and Hematology and Breast Cancer at BCM. Dr. Rimawi holds certifications in Internal Medicine and Medical Oncology from the American Board of Internal Medicine. He is a member of the American College of Physicians, American Society of Clinical Oncology and the American Medical Association.In addition to English, Dr. Rimawi speaks Arabic. Dr. Rimawi is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Paget Disease of the Breast. Dr. Rimawi is currently accepting new patients.

Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required

Office

1400 Holcombe Blvd Unit 428, 
Houston, TX 
 (0.6 miles away)
713-792-2813
Languages Spoken:
English
See accepted insurances

Hagop Kantarjian is an Oncologist practicing medicine in Houston, Texas. Dr. Kantarjian is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Splenectomy.

Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

UT MD Anderson Cancer Center

1515 Holcombe Blvd, 
Houston, TX 
 (0.3 miles away)
713-792-8850
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Neeta Somaiah is an Oncologist practicing medicine in Houston, Texas. Dr. Somaiah is highly rated in 28 conditions, according to our data. Her clinical expertise encompasses Liposarcoma, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Hepato-Pancreato-Biliary Surgery.

Frequently Asked Questions about Dr. Julie R. Nangia

How do I make an appointment with Dr. Julie R. Nangia?

You can book an appointment with Dr. Julie R. Nangia by calling their office at 713-873-4900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Julie R. Nangia a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Julie R. Nangia is classified as an Elite expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Julie R. Nangia specialize in?

While Dr. Julie R. Nangia is a Hematology Oncology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Familial Pancreatic Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Julie R. Nangia participate in research or clinical trials?

Yes. Dr. Julie R. Nangia has published 32 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Julie R. Nangia's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Julie R. Nangia accept my insurance?

Dr. Julie R. Nangia accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 713-873-4900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nangia's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile